Lupin has received the Establishment Inspection Report (EIR) from the USFDA for its Inhalation Research Center located at Coral Springs, Florida. The facility was inspected by the USFDA, between 19 February 2020 and 26 February 2020, on behalf of the UK MHRA for Lupin's generic Fostair application to the UK MHRA.
Lupin's Inhalation Research Center at Coral Springs, Florida, inaugurated in August 2015, focuses on research and development of respiratory products for the treatment of asthma, chronic obstructive pulmonary diseases and other respiratory ailments.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
